۲:۲۶ : ساعت ۱۳۹۸/۰۲/۰۶ : تاريخ

  ENGLISH

  ارتباط با ما       لينک هاي مفيد       


CV مربوط به مريم  كشوري
Doctor Maryam Keshvari Address: Iranian Blood Transfusion Organization (IBTO), Sheykh Faslollal and Hemmat cross way, next to Milad tower,Tehran ,Iran Email Address: M.Keshvari@ibto.ir , Maryamkeshvari@ yahoo.com Employment Records 2000 to present Infectious Diseases Specialist Associated Professor of Iranian Blood Transfusion Organization 2000-5.2013 Hepatitis Clinic Tehran blood Transfusion Organization, Tehran, Iran 1996-2000 Participating as Infectious Diseases Specialist Emam Khomeini Hospital under the Supervision Of Tehran University 1995-1996 General Physician 1987-1995 Assistant, Junior G.p. Different Hospitals in Tehran under the Supervision of Iran Medical University Education Tehran University, Tehran, Medical School (1996-2000) infectious diseases specialty Iran University, Tehran, Medical School (1987-1995) General Physician Thesis title: Investigation of three antibiotic regimens in cancer neutropenic patients hospitalized in Emam Khomeini hospital, Tehran between the years 1999-2000 Publications: 1- Alavian SM, Attarchi Z, Hajibeigi B, Keshvari M .Investigation of intrafamilial transmission pattern of HBV in patients referred to hepatitis clinic of Tehran blood transfusion organization. Journal of medical laboratory sciences research center.vol 7 No.23 Spring 2004 2- Alavian SM, Ahmadzad Asl M, Keshvari M.Efficacy and safety of interferon alpha and ribavirin in chronic hepatitis C patients , Hepatitis monthly , spiring 2006 Vol 2 Iss – 1 3- Kabir A, Keshvari M, Alavian SM .Efficacy of HBV vaccination in isolated HBC antibody positive patients , Govaresh 2007 4- Kabir A, Keshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti –HBc but negative HBsAg and anti HBs, Hum Vaccin. 2008 Sep-Oct;4(5):379-83. 5- Yousefinejad V., Esmeil Nasab N., Arabzadeh M., Soori M., Keshvari M., Soltanian E. Effect of education on awareness level of blood donors about transfusion-transmitted infections, Blood , vol 4 No 5 winter 2008 6- Alavian SM, Abolghasemi H ,Miri SM, Keshvari M ,Karimi Elizee P ,Behnava B. Safety and efficacy of Pegylated Interferon Alfa-2a for the treatment of hepatitis C in patients with Major Thalassemia ,Iranian Journal of Blood and Cancer, vol 1 No 4 :129-137 7- Seyed-Moayed Alavian, Seyyed Mohammad Miri, Maryam Keshvari, Pegah Karimi Elizee, Bita Behnava, Seyed-Vahid Tabatabaei, and Kamran Bagheri Lankarani. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia,Transfusion, 2009 vol 49: 2196-2199 8- M Keshvari, SM Alavian*, B Behnava, SM Miri, P Karimi Elizee, SV Tabatabaei. Distribution of Hepatitis C Virus Genotypes in Iranian Patients with Congenital Bleeding Disorders, Iranian Red Crescent Medical Journal, 2010; 12(6):608-614 9- Bita Behnava, Maryam Keshvari, Seyyed Mohammad Miri, Pegah Karimi Elizee, Seyed-Moayed Alavian. Reactivation of Brucellosis during Pegylated Interferon alpha therapy in a Thalassemic Patient with Chronic Hepatitis C, Experimental and Clinical Hepathology, 2011; 7(1-2):57-59 10- Seyed-Moayed Alavian, Seyyed Mohammad Miri, Seyed-Vahid Tabatabaei, Maryam Keshvari, Bita Behnava*, Pegah Karimi Elizee*, Nastaran Mahboobi. Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic patients, Gut and Liver, Vol. 5, No. 3, September 2011, pp. 1-8 11- Seyed-Moayed Alavian, Seyed Vahid Tabatabaei, Maryam Keshvari, Bita Behnava, Seyyed Mohammad Miri, Pegah Karimi Elizee2 and Kamran Bagheri Lankarani. Peginterferon a-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases, Liver International,2010; 1173-1180 12- Heidar Sharafi, Ali Pouryasin, Seyed Moayed Alavian, Bita Behnava, Maryam Keshvari, Leila Mehrnoush, Shima Salimi, Osveh Kheradvar . Development and Validation of a Simple, Rapid and Inexpensive PCRRFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response, Hepat Mon.2012;12(3):190-195 13- Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, Zamani F, Amini Kafiabad S, Gharehbaghian A, Hajibeigy B, Lankarani KB. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012 Jun;12(6):372-81. doi: 10.5812/hepatmon.6592. 14-Alireza Mehrazmay, Seyed Moayed Alavian, , * Maziar Moradi-Lakeh, Mahdi Mokhtari PayamAmir Hashemi-Meshkini, , Bita Behnava, Seyyed Mohammad Miri, Pegah Karimi Elizee Seyed Vahid Tabatabaee, Maryam Keshvari, and Kamran Bagheri . Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran. Hepatitis Monthly. 2013 August; 13(9): e10236 15-Mohammad Abbasinazari, Bita Behnava, Yunes Panahi, Azita Hajhossein Talasaz, Shima Salimi, Maryam Keshvari Leila Mehrnoush, Pegah karimi Elizee, Mohammad Gholami Fesharaki, Mansour Asgharinia, and Seyed Moayed Alavian.Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference? Hepatitis Monthly. 2013 August; 13(8): e11138 16-Heidar Sharafi , Ali Pouryasin Seyed Moayed Alavian Bita Behnava , Maryam Keshvari, Shima Salimi , Leila Mehrnoush , and Ahmad Fatemi. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepatitis Monthly. 2012 December; 22(12): e8387
 
صفحه اصلي      
ورود اعضا      
اخبار      
اطلاع رساني       
بانک اطلاعات محققين       
سازمان انتقال خون       
موسسه عالي آموزشي و پژوهشي طب انتقال خون      
مجله پژوهشي خون       
 
 By: Peyvandco.com طرح هاي تحقيقاتي | محققين | گزارش طرح | ارتباط با ما | نقشه سايت